Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Buy
- Symbol (CGON)
- Company CG Oncology, Inc. Common stock
- Price $37.74
- Changes Percentage (-0.34%)
- Change -$0.13
- Day Low $37.34
- Day High $39.00
- Year High $50.23
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $63.50
- High Stock Price Target $75.00
- Low Stock Price Target $52.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-48,607,000
Income Statement
Quarterly
Annual
Latest News of CGON
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CG Oncology, Inc. (CGON) Stock Price, News, Quote & History - Yahoo Finance
CG Oncology, a biopharmaceutical company, will have its CEO partake in a fireside chat in New York on Sept. 6, 2024. The company is dedicated to advancing treatments for bladder cancer patients. The e...
By Yahoo! Finance | 2 weeks ago -
Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock
Cg Oncology Inc. (NASDAQ:CGON) is a company focusing on bladder-sparing treatments for bladder cancer patients. Analysts are optimistic about its drug candidate, cretostimogene, with a projected globa...
By Yahoo! Finance | 2 weeks ago -
Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week
Analyzing analyst forecasts and ownership structure can aid in evaluating a company's future performance. For instance, CG Oncology, Inc. is predominantly owned by institutions, with Decheng Capital L...
By Yahoo! Finance | 2 months ago